# Atorvastatin Plus Ezetimibe on Coronary Plaque Progression

Study · id `cardio:ct-nct01086020` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01086020](<https://clinicaltrials.gov/study/NCT01086020>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01086020

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT01086020. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2011-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT01086020, source copy `cardio:ctgov-nct01086020-2011-04-04`, retrieved 2026-10-26)
- Start date: 2010-01 (registry gives no type) (ClinicalTrials.gov record NCT01086020, source copy `cardio:ctgov-nct01086020-2011-04-04`, retrieved 2026-10-26)
- Primary completion: 2011-12 (anticipated) (ClinicalTrials.gov record NCT01086020, source copy `cardio:ctgov-nct01086020-2011-04-04`, retrieved 2026-10-26)
- Completion: 2012-12 (anticipated) (ClinicalTrials.gov record NCT01086020, source copy `cardio:ctgov-nct01086020-2011-04-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01086020, source copy `cardio:ctgov-nct01086020-2011-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01086020-2011-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Atorvastatin Plus Ezetimibe on Coronary Plaque Progression
- Acronym: AEPP
- Condition: Coronary Artery Disease
- Intervention (Drug): atorvastatin
- Intervention (Drug): atorvastatin plus ezetimibe
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

## Provenance

Content hash: 62a44d19a2f7849d951446ee94f5826b0987a0a56df12247e63d8bbec5bac83e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
